Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.
Also called NCT05199129
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 166 participants
- Registry
-
NCT05199129
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT05199129. Randomized; double masking; primary purpose treatment. Start 2021-11-17 (actual); primary completion 2022-09-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
- Condition
- Hypertension
- Intervention (Drug)
- HCP1904-3
- Intervention (Drug)
- RLD2001-1
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct05199129- Content hash
144ef9fc04477f8b61367b21eb458efe198817284512930036f5e390edfd8c44